Last reviewed 2026-05-14 · How we verify

Barbonin (ETHAVERINE)

Phase 2 active Small molecule Quality 22/100

Barbonin (generic name: ETHAVERINE) is a ethaverine drug. It is currently in Phase 2 development for Cerebral ischemia, Peripheral vascular disease.

Barbonin works by improving blood flow to the affected areas of the body.

Barbonin, also known as ethaverine, is a small molecule drug in the ethaverine class. It is used to treat cerebral ischemia and peripheral vascular disease. The commercial status of Barbonin is currently unknown, and it is not clear if it is patented or available as a generic. Further information on its pharmacokinetics and safety profile is also lacking. As a result, its use should be approached with caution and further research.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ETHAVERINE
Drug class	ethaverine
Modality	Small molecule
Therapeutic area	Hematology
Phase	Phase 2

Mechanism of action

Think of it like a traffic cop directing traffic in a busy city. Barbonin helps to improve blood flow by relaxing the muscles in the blood vessels, allowing more blood to reach the areas that need it. This can help to reduce the damage caused by lack of blood flow, such as in cerebral ischemia or peripheral vascular disease.

Approved indications

Cerebral ischemia
Peripheral vascular disease

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Barbonin CI brief — competitive landscape report
Barbonin updates RSS · CI watch RSS

Frequently asked questions about Barbonin

What is Barbonin?

Barbonin (ETHAVERINE) is a ethaverine drug, indicated for Cerebral ischemia, Peripheral vascular disease.

How does Barbonin work?

Barbonin works by improving blood flow to the affected areas of the body.

What is Barbonin used for?

Barbonin is indicated for Cerebral ischemia, Peripheral vascular disease.

What is the generic name of Barbonin?

ETHAVERINE is the generic (nonproprietary) name of Barbonin.

What drug class is Barbonin in?

Barbonin belongs to the ethaverine class. See all ethaverine drugs at /class/ethaverine.

What development phase is Barbonin in?

Barbonin is in Phase 2.

Drug class: All ethaverine drugs
Therapeutic area: All drugs in Hematology
Indication: Drugs for Cerebral ischemia
Indication: Drugs for Peripheral vascular disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing